Angiotensin Converting Enzyme Inhibitors

Angiotensin Converting Enzyme Inhibitors

This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hypertension 1990-04, Vol.3 (4), p.331-337
1. Verfasser: Bauer, J H
Format: Artikel
Sprache:eng
Schlagworte:
Angiotensin converting enzyme inhibitors
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
captopril
efficacy
enalapril
Humans
Kidney - drug effects
lisinopril
renal function
safety
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 337
container_issue 4
container_start_page 331
container_title American journal of hypertension
container_volume 3
creator Bauer, J H
description This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension. Am J Hypertens 1990;3:331-337
doi_str_mv 10.1093/ajh/3.4.331
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79796286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79796286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-645e3696c2bdf467e03d2bdf2d0acfb3f006f3f40f53f512137e23fe6270cb453</originalsourceid><addsrcrecordid>eNo9kM1LAkEYh4cozKxT58BTBLE6M-98uEcTTcOKoCC8DPsxo2PurM2skf31rSie3heeh9_hQeia4A7BMXST5aILHdYBICeoSWJGIkkpP0VN3It5JLEg5-gihCXGmAlBGqhBSS9mjDfRXd_NbVlpF6xrD0r3o31l3bw9dH_bQrcnbmFTW5U-XKIzk6yCvjrcFvoYDd8H42j6-jgZ9KdRBpRWkWBcg4hFRtPcMCE1hnz30hwnmUnBYCwMGIYNB8MJJSA1BaMFlThLGYcWut3vrn35vdGhUoUNmV6tEqfLTVAylrGgPVGL93sx82UIXhu19rZI_FYRrHZdVN1FgWKq7lLbN4fZTVro_OgeQtQ82nMbKv17xIn_UkKC5Gr8OVPP4mn09jB7UQz-AdvabH0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79796286</pqid></control><display><type>article</type><title>Angiotensin Converting Enzyme Inhibitors</title><source>MEDLINE</source><source>Oxford University Press Archive</source><creator>Bauer, J H</creator><creatorcontrib>Bauer, J H</creatorcontrib><description>This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension. Am J Hypertens 1990;3:331-337</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1093/ajh/3.4.331</identifier><identifier>PMID: 2189445</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Angiotensin converting enzyme inhibitors ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; captopril ; efficacy ; enalapril ; Humans ; Kidney - drug effects ; lisinopril ; renal function ; safety</subject><ispartof>American journal of hypertension, 1990-04, Vol.3 (4), p.331-337</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-645e3696c2bdf467e03d2bdf2d0acfb3f006f3f40f53f512137e23fe6270cb453</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2189445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bauer, J H</creatorcontrib><title>Angiotensin Converting Enzyme Inhibitors</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension. Am J Hypertens 1990;3:331-337</description><subject>Angiotensin converting enzyme inhibitors</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>captopril</subject><subject>efficacy</subject><subject>enalapril</subject><subject>Humans</subject><subject>Kidney - drug effects</subject><subject>lisinopril</subject><subject>renal function</subject><subject>safety</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1LAkEYh4cozKxT58BTBLE6M-98uEcTTcOKoCC8DPsxo2PurM2skf31rSie3heeh9_hQeia4A7BMXST5aILHdYBICeoSWJGIkkpP0VN3It5JLEg5-gihCXGmAlBGqhBSS9mjDfRXd_NbVlpF6xrD0r3o31l3bw9dH_bQrcnbmFTW5U-XKIzk6yCvjrcFvoYDd8H42j6-jgZ9KdRBpRWkWBcg4hFRtPcMCE1hnz30hwnmUnBYCwMGIYNB8MJJSA1BaMFlThLGYcWut3vrn35vdGhUoUNmV6tEqfLTVAylrGgPVGL93sx82UIXhu19rZI_FYRrHZdVN1FgWKq7lLbN4fZTVro_OgeQtQ82nMbKv17xIn_UkKC5Gr8OVPP4mn09jB7UQz-AdvabH0</recordid><startdate>19900401</startdate><enddate>19900401</enddate><creator>Bauer, J H</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900401</creationdate><title>Angiotensin Converting Enzyme Inhibitors</title><author>Bauer, J H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-645e3696c2bdf467e03d2bdf2d0acfb3f006f3f40f53f512137e23fe6270cb453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Angiotensin converting enzyme inhibitors</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>captopril</topic><topic>efficacy</topic><topic>enalapril</topic><topic>Humans</topic><topic>Kidney - drug effects</topic><topic>lisinopril</topic><topic>renal function</topic><topic>safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, J H</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, J H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin Converting Enzyme Inhibitors</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>1990-04-01</date><risdate>1990</risdate><volume>3</volume><issue>4</issue><spage>331</spage><epage>337</epage><pages>331-337</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><abstract>This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension. Am J Hypertens 1990;3:331-337</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>2189445</pmid><doi>10.1093/ajh/3.4.331</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0895-7061
ispartof American journal of hypertension, 1990-04, Vol.3 (4), p.331-337
issn 0895-7061
1941-7225
language eng
recordid cdi_proquest_miscellaneous_79796286
source MEDLINE; Oxford University Press Archive
subjects Angiotensin converting enzyme inhibitors
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
captopril
efficacy
enalapril
Humans
Kidney - drug effects
lisinopril
renal function
safety
title Angiotensin Converting Enzyme Inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T14%3A00%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20Converting%20Enzyme%20Inhibitors&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Bauer,%20J%20H&rft.date=1990-04-01&rft.volume=3&rft.issue=4&rft.spage=331&rft.epage=337&rft.pages=331-337&rft.issn=0895-7061&rft.eissn=1941-7225&rft_id=info:doi/10.1093/ajh/3.4.331&rft_dat=%3Cproquest_cross%3E79796286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79796286&rft_id=info:pmid/2189445&rfr_iscdi=true